Supplementary Table 1. RT PCR primers for experiment in Figure 1

HGNC Symbol	NCBI Gene ID	Forward (5'→3')	Reverse (5'→3')	Approx. Amplicon	Reference
ALDH1A3	NM_000693	TCTCGACAAAGCCCTGAAGT	GGCGTTGTAGCAGTTGATCC	~100–120 bp	Mol Cancer Res (2008) 6 (7): 1146–53
PROM1 (CD133)	NM_006017	TGGATGCAGAACTTGACAACGT	ATACCTGCTACGACAGTCGTGGT	~180 bp	

Supplementary Table 2. Antibodies

Name	Vendor	Catalog number	Conditions
LC3B (MAP1LC3B)	Abcam	ab48394	1:500
Anti-SQSTM1 / p62	Abcam	ab207305	1:300
p16	Cell Signaling	4824	1:500
Bmi1 (D20B7)	Cell Signaling	6964	1:250
beta Actin Antibody (C4)	SantaCruz Biotechnology	sc-47778	1:1000




Figure S1. Triple negative breast cancer demonstrates enhance stemness over any other types of breast cancer. Mean difference in mRNA expression (log2 RSEM, gene-wise z-scored) between Triple-Negative Breast Cancer (TNBC; PAM50 Basal-like proxy, n = 171) and non-TNBC (n = 810) tumors from the TCGA Breast Invasive Carcinoma PanCancer Atlas cohort (n = 981 total). Positive values (red) indicate higher expression in TNBC; negative values (blue) indicate lower expression in TNBC. Stemness transcription factors (*POU5F1/OCT4, MYC, NANOG*) and the surface markers *PROM1 (CD133)* and *CD24* are significantly upregulated in TNBC, while *ALDH1A1* and *KLF4* are significantly downregulated. All comparisons two-sided Mann-Whitney U test, Benjamini-Hochberg FDR-corrected across 10 genes (***FDR < 0.001, **FDR < 0.01, *FDR < 0.05).

Supplementary Figure S2




Fig. S2A. **Increased stemness markers in mammospheres.** Samples of different generations of mammospheres obtained from MB-231-231 TNBC (parental) cells were WBed and probed with stemness markers.



Fig. S2B. **CSC treatment with OXPHOS inhibitors results in increased autophagy.** **(**P)arental or third generation CSC (mammospheres) from TNBC cells MDA-MB-231 and MDA-MB-468 have been treated with OXPHOS inhibitors AMX and FSS for 3 days and resulting cell extracts were Western blotted following probing with LC3 antibody.




Fig. S2C. **Expression of OXPHOS markers is increased from in G1 (top) to G2, G3 generation of mammospheres (bottom).** Western blots with five mitochondrial respiratory proteins from the samples of parental (P) and CSC-like cells (mammospheres) of TNBC cells of different generations.






Fig. S2D. OxyBlot from MDA-MB-231 mammospheres treated with OXPHOS inhibitors. 1. 468-CSC; 2. 231-CSC; 3. Positive control: MDA-MB-468 cell extracts treated with 5 mM $FeCl_3/H_2O_2$ (Fenton reaction) for 30 min before derivatization; 4. Negative control 468-CSC without DNPH; 5. 231-CSC treated with AMX; 6. 468-CSC treated with AMX; 7. 468-CSC treated with FSS; 8. Negative control 231-CSC without DNPH; 9. 231-CSC treated with FSS





	MDA MB 468				Average
PARENTAL	28	18	20	14	20
PARENTAL + AMX	13	13	14	9	12,25
PARENTAL + FSS	6	6	6	4	5,5
RESISTANT	28	26	16	23	23,25

	MDA MB 231				Average
PARENTAL	13	14	15	13	13,75
PARENTAL + AMX	7	7	7	7	7
PARENTAL + FSS	5	6	5	5	5,25
RESISTANT	32	18	26	20	24

Figure S3. Inhibition of mammosphere formation upon treatment with OXPHOS inhibitors. Mammospheres from (P)arental MDA-MB-231, MDA-MB-468 or corresponding resistant to Cisplatin counterparts (R) were grown till generation 2 and were treated with OXPHOS inhibitors AMX or FSS before processing to 2d generation. Representative images were taken after 5 days. The number of mammospheres were calculated and plotted as bar diagram in Figure 3. Calculations are shown in the tables.




Figure S4. Inhibition of mammosphere formation upon treatment with OXPHOS inhibitors. Mammospheres from (P)arental MDA-MB-231, MDA-MB-468 or corresponding resistant to Cisplatin counterparts (R) were grown till generation 2 and were treated with OXPHOS inhibitors AMX or FSS before processing to 2d generation. Representative images were taken after 5 days. The number of mammospheres were calculated and plotted as bar diagram in Figure 3. Calculations are shown in the tables.

Supplementary Figure S5

Ethics declaration

Animal subject

This study was conducted in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines as well as the following guidelines for animal welfare and/or reporting: IACUC.

This study was approved by the Gebze Technical University.

(Approval No. 2025-03; 2024-08)

HAYVAN DENEYLERİ YEREL ETİK KURULU

TOPLANTI TARİHİ	KARAR NO	İLGİ	PROJE YÜRÜTÜCÜSÜ
18.09.2024	2024-08		Alex LYAKHOVICH

Sabancı Üniversitesinde görev yapmakta olan Alex LYAKHOVICH 'in yapmış olduğu başvuru görüşülmüş olup "Warburg etkisinin 100 Yılı: Kemorezistan tümörlerde glikoz ve oksidatif fosforilasyonun denge dinamiklerinin biyosensörler kullanılarak incelenmesi" konu başlıklı TÜBİTAK projesi altında gerçekleştirilecek olan deneysel çalışmanın etik kurallara uygun olduğuna "Oy çokluğu" karar verilmiştir.

Etik Onay Geçerlilik Süresi:	3 Yıl

GÖREVİ	ADI SOYADI	İMZA
Başkan	Prof. Dr. Tamer YAĞCI	
Başkan Yardımcısı (Veteriner Hekim)	Doç. Dr. Zeynep SOYER SARICA	
Üye	Prof. Dr. Uygar Halis TAZEBAY	
Üye	Prof. Dr. Mahmut DURMUŞ	KATILMADI
Üye	Prof. Dr. Ferruh ÖZCAN	
Üye	Dr. Öğr. Üyesi Pınar PİR	
Üye	Prof. Dr. Elif Damla ARISAN	KATILMADI
Üye	Vet. Hek. Dr. Ahmet SAİT	
Üye	Vet. Teknikeri Leyla DİKMEDAŞ	
Üye	Recep UYSAL	KATILMADI

HAYVAN DENEYLERİ YEREL ETİK KURULU

TOPLANTI TARİHİ	KARAR NO	İLGİ	PROJE YÜRÜTÜCÜSÜ
17.01.2025	2025-03		Alex LYAKHOVICH

Sabancı Üniversitesinde görev yapmakta olan Alex LYAKHOVICH'in yapmış olduğu başvuru görüşülmüş olup 'Mitokondriyal Bozukluğu İndükleyen Antibiyotiklerin Kanser Kemodirencine Karşı Özgün Kemoterapötik Ajanlar Olarak Kullanılması' konu başlıklı TÜBİTAK projesi altında gerçekleştirilecek olan deneysel çalışmanın ilgili mevzuat hükümleri çerçevesinde etik kurallara uygun olduğuna "Oy çokluğu" karar verilmiştir.

Etik Onay Geçerlilik Süresi:	3 Yıl

GÖREVİ	ADI SOYADI	İMZA
Başkan	Prof. Dr. Tamer YAĞCI	
Başkan Yardımcısı (Veteriner Hekim)	Doç. Dr. Zeynep SOYER SARICA	
Üye	Prof. Dr. Uygar Halis TAZEBAY	
Üye	Prof. Dr. Mahmut DURMUŞ	
Üye	Prof. Dr. Ferruh ÖZCAN	
Üye	Dr. Öğr. Üyesi Pınar PİR	KATILMADI
Üye	Prof. Dr. Elif Damla ARISAN	KATILMADI
Üye	Vet. Hek. Ahmet SAİT	
Üye	Vet. Teknikeri Leyla DİKMEDAŞ	
Üye	Recep UYSAL	KATILMADI

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
231-CSC_1	Rawdata	Exponential (Fallback)	1	0,752		5,54	
231-CSC_2	Rawdata	Exponential (Fallback)	0,996	1,03		0,842	
231-CSC_3	Rawdata	Exponential (Fallback)	0,998	0,878		2,65	
231-CSC_4	Rawdata	Exponential (Fallback)	0,999	0,709		8,28	

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
231-CSC-AMX_5	Rawdata	Sigmoid	0,985	0,353	1870		11,6
231-CSC-AMX_6	Rawdata	Sigmoid	0,986	0,583	281		4,34
231-CSC-AMX_7	Rawdata	Sigmoid	0,881	0,541	301		4,58
231-CSC-AMX_8	Rawdata	Sigmoid	0,967	0,286	1170		11,9




Figure S6. OXPHOS inhibitor AMX reduces tumor growth derived from CSC. NMRI-nu mice injected with MDA-MB-231-CSC-like cells (mammospheres) were orally administrated with 100mg/kg AMX or PBS twice a week. Tumor sizes were measured weekly (left). Tumor volumes at week 8 and tumor growth rates were calculated (right).

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
468-CSC_9	Rawdata	Exponential (Fallback)	0,985	0,694		8,07	
468-CSC_10	Rawdata	Exponential (Fallback)	0,989	0,65		13,4	
468-CSC_11	Rawdata	Exponential (Fallback)	0,996	0,744		9,02	
468-CSC_12	Rawdata	Exponential (Fallback)	0,98	0,678		10,7	

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
468-CSC-AMX_13	Rawdata	Sigmoid	0,971	0,373	532		6,72
468-CSC-AMX_14	Rawdata	Sigmoid	0,975	0,651	268		3,47
468-CSC-AMX_15	Rawdata	Sigmoid	0,978	0,563	309		4,04
468-CSC-AMX_16	Rawdata	Sigmoid	0,986	0,479	395		5,07




Figure S7. OXPHOS inhibitor AMX reduces tumor growth derived from CSC. NMRI-nu mice injected with MDA-MB-468-CSC-like cells (mammospheres) were orally administrated with 100mg/kg AMX or PBS twice a week. Tumor sizes were measured weekly (left). Tumor volumes at week 8 and tumor growth rates were calculated (right).

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
CSC_1	Rawdata	Sigmoid	0,297	4,4	79,9		0,748
CSC_3	Rawdata	Sigmoid	0,783	0,155	1020		16,3
CSC_5	Rawdata	Exponential (Fallback)	0,969	0,305		51,4	
CSC_7	Rawdata	Exponential (Fallback)	0,796	0,135		97,4	

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
CSC-AMX_1	Rawdata	Sigmoid	0,9	0,532	346		4,06
CSC-AMX_3	Rawdata	Exponential (Fallback)	0,34	0,0482		57,4	
CSC-AMX_4	Rawdata	Exponential (Fallback)	0,291	-0,0629		129	
CSC-AMX_5	Rawdata	Sigmoid	0,438	0,268	332		3,39
CSC-AMX_6	Rawdata	Exponential (Fallback)	0,715	-0,353		137	
CSC-AMX_7	Rawdata	Sigmoid	0,967	0,403	794		6,45




Figure S8. Chemoprevention in mice orally administrated with OXPHOS inhibitor AMX. Balb/c mice were given 100mg/kg AMX or PBS twice a week for 14 days followed by injection with MDA-MB-231 (P)arental cells. Tumor sizes were measured weekly (left). Tumor growth rates and tumor volumes at week 7 post-injection were calculated (right).

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
231-CSC_1	Rawdata	Sigmoid	0,947	0,911	1330		5,35
231-CSC_2	Rawdata	Sigmoid	0,961	0,462	2450		7,54
231-CSC_3	Rawdata	Sigmoid	0,971	0,499	2800		7,34
231-CSC_4	Rawdata	Sigmoid	0,988	0,671	8150		9,4
231-CSC_5	Rawdata	Sigmoid	0,964	0,478	1590		7,29

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
231-CSC-AMX_1	Rawdata	Sigmoid	0,928	0,693	1030		5,38
231-CSC-AMX_2	Rawdata	Exponential (Fallback)	0,935	0,325		70,7	
231-CSC-AMX_3	Rawdata	Sigmoid	0,991	0,687	735		4,4
231-CSC-AMX_4	Rawdata	Sigmoid	0,947	0,659	566		2,19
231-CSC-AMX_5	Rawdata	Exponential (Fallback)	0,832	0,267		58,8	




Figure S9. Chemoprevention in mice orally administrated with OXPHOS inhibitor AMX (Independent experiment). NMRI-nu mice were given 100mg/kg AMX or PBS twice a week for 14 days followed by injection with MDA-MB-231 (P)arental cells. Tumor sizes were measured weekly (left). Tumor growth rates and tumor volumes at week 7 post-injection were calculated (right).

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
231-P_1	Rawdata	Exponential (Fallback)	0,952	0,297		80,7	
231-P_2	Rawdata	Sigmoid	0,92	0,428	2380		8,72
231-P_3	Rawdata	Sigmoid	0,987	0,611	795		4,26
231-P_4	Rawdata	Sigmoid	0,974	0,639	620		3,39
231-P_5	Rawdata	Exponential (Fallback)	0,971	0,399		47,1	

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
231-P-AMX_1	Rawdata	Exponential (Fallback)	0,977	0,268		116	
231-P-AMX_2	Rawdata	Sigmoid	0,793	0,479	500		3,24
231-P-AMX_3	Rawdata	Sigmoid	0,869	0,416	974		4,78
231-P-AMX_4	Rawdata	Sigmoid	0,876	0,549	1030		5,17
231-P-AMX_5	Rawdata	Sigmoid	0,983	0,538	1440		6,8




Figure S10. No chemoprevention has been observed in mice injected with MDA-MB-231 (P)arental cells orally preadministrated with OXPHOS inhibitor AMX. Balb/c mice were given 100mg/kg AMX or PBS twice a week for 14 days followed by injection with MDA-MB-231 (P)arental cells. Tumor sizes were measured weekly (left). Tumor growth rates and tumor volumes at week 7 post-injection were calculated (right).

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
231-P_1	Rawdata	Exponential (Fallback)	0,962	0,338		83,2	
231-P_2	Rawdata	Sigmoid	0,938	0,391	3470		9,81
231-P_3	Rawdata	Sigmoid	0,989	0,395	1660		6,2
231-P_4	Rawdata	Exponential (Fallback)	0,999	0,317		97,8	
231-P_5	Rawdata	Exponential (Fallback)	0,986	0,349		72,9	

Sample	Source_Sheet	Model_Used	R2_Score	Growth_Rate_k	Carrying_Capacity_L	Scale_Factor_A	Anchor_Point_x0
231-P-AMX_1	Rawdata	Exponential (Fallback)	0,986	0,294		111	
231-P-AMX_2	Rawdata	Sigmoid	0,938	0,331	7910		13,3
231-P-AMX_3	Rawdata	Exponential (Fallback)	0,837	0,245		163	
231-P-AMX_4	Rawdata	Sigmoid	0,871	0,593	1050		4,7
231-P-AMX_5	Rawdata	Sigmoid	0,981	0,635	1110		5,49




Figure S11. No chemoprevention has been observed in mice injected with MDA-MB-231 (P)arental cells orally preadministrated with OXPHOS inhibitor AMX (independent experiment). NMRI-nu mice were given 100mg/kg AMX or PBS twice a week for 14 days followed by injection with MDA-MB-231 (P)arental cells. Tumor sizes were measured weekly (left). Tumor growth rates and tumor volumes at week 7 post-injection were calculated (right).

	size (mm)															
Samples	W1_w	W1_l	W1_h	W3_w	W3_l	W3_h	W5_w	W5_l	W5_h	W7_w	W7_l	W7_h	W8_w	W8_l	W8_h
231-CSC_1	3.60	3.67	4.03	5.30	5.53	5.60	7.97	7.80	7.87	12.47	12.97	13.07	16.13	16.57	17.00
231-CSC_2	4.40	4.15	4.50	5.37	5.33	5.43	8.27	8.53	8.23	12.83	12.97	12.80	18.60	18.37	18.53
231-CSC_3	4.17	4.27	3.90	5.77	5.30	5.67	8.27	8.43	8.23	13.33	13.77	13.00	18.25	17.70	18.55
231-CSC_4	3.87	4.10	4.17	5.40	5.63	5.63	8.50	8.77	8.67	13.17	13.13	13.27	16.87	16.80	17.00
231-CSC-AMX_5	3.70	3.60	3.93	5.47	5.50	5.80	7.37	7.17	7.30	8.63	8.33	8.07	9.87	8.90	9.67
231-CSC-AMX_6	4.03	4.20	4.00	5.67	5.63	5.87	6.73	6.80	6.87	7.97	7.63	8.13	8.00	7.83	7.70
231-CSC-AMX_7	4.10	3.97	4.03	5.97	6.13	6.03	6.63	6.33	6.33	8.07	8.43	8.40	7.40	7.83	8.00
231-CSC-AMX_8	4.17	4.30	4.07	6.07	6.03	5.97	6.27	6.23	6.17	7.77	7.80	7.90	8.13	8.20	8.47
468-CSC_9	4.00	4.03	3.93	5.93	6.07	6.03	9.57	9.20	9.37	12.27	12.30	12.03	16.27	16.23	16.07
468-CSC_10	3.93	4.17	4.03	6.10	6.00	6.03	9.67	10.13	10.27	13.13	13.13	13.13	17.17	16.90	17.07
468-CSC_11	4.30	4.20	4.13	6.27	6.07	6.17	9.73	10.27	10.20	14.57	14.57	14.57	19.10	19.17	19.13
468-CSC_12	4.27	4.03	4.07	6.33	6.17	6.13	10.00	10.37	10.17	12.80	12.80	12.93	17.13	17.30	16.83
468-CSC-AMX_13	4.23	4.03	4.17	6.30	6.23	6.27	7.27	7.10	7.50	7.93	8.00	8.03	8.80	8.70	8.93
468-CSC-AMX_14	4.20	4.17	4.17	6.17	6.30	6.20	7.07	7.50	7.43	7.60	7.67	7.63	8.27	8.23	7.97
468-CSC-AMX_15	4.23	4.10	4.10	6.17	6.50	6.40	7.37	6.77	7.20	8.10	8.27	8.17	8.10	8.27	8.17
468-CSC-AMX_16	4.17	4.00	4.17	6.17	6.43	6.37	7.40	7.13	6.90	8.47	8.30	8.17	8.90	8.60	8.27

	volume = w*h*l / 2 (mm^3)				
W1	W3	W5	W7	W8
26.6	82.1	244.4	1056.1	2271.8
41.1	77.8	290.4	1065.0	3165.7
34.7	86.6	287.0	1193.1	2996.1
33.0	85.7	322.9	1147.1	2408.6
26.2	87.2	192.7	290.2	424.4
33.9	93.6	157.2	247.3	241.3
32.8	110.4	133.0	285.7	231.9
36.4	109.2	120.4	239.3	282.3
31.7	108.6	412.2	907.8	2121.3
33.1	110.4	502.8	1132.6	2475.7
37.3	117.2	509.6	1545.4	3502.2
35.0	119.8	527.0	1059.5	2494.8
35.6	123.0	193.5	254.9	342.0
36.5	120.4	197.0	222.4	271.1
35.6	128.3	179.5	273.4	273.4
34.7	126.3	182.1	286.9	316.4

	volume = min^2 * max / 2 (mm^3)				
W1	W3	W5	W7	W8
26.1	78.7	242.3	1015.4	2212.4
38.8	77.3	280.2	1051.3	3137.2
31.7	81.0	280.2	1126.7	2905.8
31.1	82.1	313.1	1144.1	2399.0
25.5	86.7	189.2	280.9	390.8
32.3	93.1	155.7	237.0	237.2
32.3	107.4	133.0	273.3	219.0
34.5	108.0	119.2	238.3	280.0
30.9	106.2	404.9	888.1	2099.5
31.2	109.8	479.7	1132.6	2451.5
36.7	115.3	483.2	1545.4	3490.0
34.7	119.1	508.3	1059.5	2427.5
34.4	122.4	189.0	252.8	338.1
36.5	117.9	185.6	220.5	262.3
35.6	121.7	168.7	267.9	267.9
33.3	121.1	176.2	282.3	304.1

Figure S12A. Raw data on experiments with OXPHOS inhibitor AMX. (related to Fig. S5, S6, S9). NMRI-nu mice were injected with MDA-MB-231 (P)arental cells or CSC-like cells (mammospheres) followed by oral administration of 100mg/kg AMX or PBS twice a week. Tumor sizes were measured weekly (left). Tumor volumes were calculated by 2 different formulas (table on the right, yellow).

	size (mm)																	
Samples	W1_w	W1_l	W1_h	W2_w	W2_l	W2_h	W4_w	W4_l	W4_h	W5_w	W5_l	W5_h	W6_w	W6_l	W6_h	W7_w	W7_l	W7_h
231-P_1	5.9	6.6	7.4	8.2	7.1	8	8.9	7.4	9.3	11.2	7.5	10.5	12.6	8.3	10.5	17.3	8.9	12.2
231-P_2	6	6.3	5.6	7.9	8.4	6.3	8.5	9.9	7.3	9.4	9.9	7.7	16.2	10.1	9.2	16.3	10.8	9.5
231-P_3	8.4	10	4.5	10.2	9.6	5.3	10.9	11.6	8.3	12.3	11.2	8.5	15.1	12.2	9	15.4	13.3	9.3
231-P_4	5.2	8.1	5.9	6.3	9.8	6.4	8	11.5	7.7	7.9	14.6	8	8.7	15.1	10.1	13.9	15.8	8.2
231-P_5	7.8	5.9	4.6	7.9	6.8	7.6	9.8	6.1	9.7	9.4	7.9	10.2	9.6	8.8	13.8	10.1	11.2	15.2
231-P-AMX_1	7	7.3	6.2	8.1	7.8	8	9.2	8.8	8.6	9.5	10.1	9.3	8.9	13.4	10.7	10.8	13.6	12.2
231-P-AMX_2	7.1	5.6	6.5	9.2	6.9	7.2	10.9	9.4	6.7	7.6	11.3	8.7	8.1	15.2	12.4	6.7	16.7	15.2
231-P-AMX_3	8.5	7.4	6.2	8.3	9.6	6.2	11.9	9.3	9.9	12	10.7	9.2	9.3	11.9	9	9.7	16.2	12.7
231-P-AMX_4	5.8	6	7.4	6.1	8.2	6.9	10.9	8.7	6.8	12.3	11.9	10.3	9.6	8.8	13.8	15.3	11.4	10.1
231-P-AMX_5	5.6	6.1	4.6	6.7	4.9	8.9	9.6	7.9	6.8	10.3	9.5	9.4	11.5	8.8	13.8	14.2	10.5	10.4
231-CSC_1	7	6.1	5.9	8.4	6.7	6.3	8.3	7.9	7.7	13.1	9.6	8.7	11.3	15.2	11.6	12.3	18.8	10.5
231-CSC_2	6	5.7	6.1	7.9	6.8	5.8	9.2	8.7	11.2	14.7	12.9	9.6	16.2	10.1	9.2	17.4	11.3	12.7
231-CSC_3	6.1	6.5	6.9	10.2	7.7	5.2	9.6	11.8	10.4	13.4	12.3	9	15	12.2	11.6	12.4	16.5	12.5
231-CSC_4	4.9	5.2	7.8	5.7	6.1	6.4	6.7	5.4	8.6	10.6	10.3	9.1	14.9	11.9	10.1	16.3	12.9	13.1
231-CSC_5	7.3	4.7	7.8	6.7	5.9	9.6	8.5	6.3	10.2	11	7.1	15.4	16.3	8.4	17.5	16.8	8.9	18.1
231-CSC-AMX_1	5.8	5.4	7.9	6.4	7.1	6.6	6.6	7.6	8.5	10.6	9.3	9.1	10.7	10.9	12.5	10.3	11.9	13.7
231-CSC-AMX_2	6.7	6.2	8.4	6.7	7.4	8.8	6.3	8.4	9.2	8.6	12.2	7.3	10.5	10.3	9.8	11.6	13.3	10.3
231-CSC-AMX_3	5.1	6.3	7	5.4	7.8	6.9	8.7	7.8	9.5	9.6	11.7	8.9	11.9	13.9	9	13.2	14.6	9.2
231-CSC-AMX_4	6.8	8.3	7.8	7.4	9.2	8.8	9.7	9.9	9.3	9.1	11.6	10.4	12.7	11.4	9.6	12.8	8.7	13.2
231-CSC-AMX_5	6.9	6.3	6.8	6.1	5.8	7	5.3	6.6	7	10.6	6	13.8	12.1	5.7	15.9	11.4	6.9	17.2

	volume = w*h*l / 2 (mm^3)					
W1	W2	W4	W5	W6	W7
144.1	232.9	306.2	441.0	549.0	939.2
105.8	209.0	307.1	358.3	752.7	836.2
189.0	259.5	524.7	585.5	829.0	952.4
124.3	197.6	354.2	461.4	663.4	900.4
105.8	204.1	289.9	378.7	582.9	859.7
158.4	252.7	348.1	446.2	638.0	896.0
129.2	228.5	343.2	373.6	763.3	850.4
195.0	247.0	547.8	590.6	498.0	997.8
128.8	172.6	322.4	753.8	582.9	880.8
78.6	146.1	257.9	459.9	698.3	775.3
126.0	177.3	252.4	547.1	996.2	1214.0
104.3	155.8	448.2	910.2	752.7	1248.5
136.8	204.2	589.1	741.7	1061.4	1278.8
99.4	111.3	155.6	496.8	895.4	1377.3
133.8	189.7	273.1	601.4	1198.1	1353.2
123.7	150.0	213.2	448.5	728.9	839.6
174.5	218.2	243.4	383.0	529.9	794.5
112.5	145.3	322.3	499.8	744.3	886.5
220.1	299.6	446.5	548.9	694.9	735.0
147.8	123.8	122.4	438.8	548.3	676.5

	volume = min^2 * max / 2 (mm^3)					
W1	W2	W4	W5	W6	W7
128.8	206.7	254.6	315.0	434.0	685.2
98.8	166.7	263.8	293.5	685.6	735.5
101.3	143.3	399.6	444.3	611.6	666.0
109.5	194.5	340.9	455.6	571.5	531.2
82.5	182.6	182.3	318.3	534.3	775.3
140.3	246.4	340.2	436.8	530.7	793.2
111.3	219.0	244.7	326.3	498.6	374.8
163.4	184.5	514.6	507.8	482.0	762.1
124.5	152.6	252.0	652.5	534.3	780.4
64.5	106.8	222.0	455.1	534.3	767.9
121.8	166.7	246.1	495.8	970.4	1036.4
99.1	132.9	423.9	677.4	685.6	1110.9
128.4	137.9	543.7	542.7	1009.2	1268.5
93.6	104.0	125.4	438.9	760.0	1356.2
86.2	167.1	202.4	388.2	617.4	716.9
115.2	145.4	185.1	438.9	715.6	726.7
161.4	197.5	182.6	325.1	504.2	705.5
91.0	113.7	289.0	463.4	563.0	617.9
191.9	251.9	428.1	480.3	585.2	499.6
136.9	117.7	98.3	248.4	258.3	409.4

Figure S12B. Raw data on chemoprevention experiment (independent experiment Fig. S8, S9). NMRI-nu mice were given 100mg/kg AMX or PBS twice a week for 14 days followed by injection with MDA-MB-231 (P)arental cells or CSC-like cells (mammospheres). Tumor sizes were measured weekly (left). Tumor volumes were calculated by 2 different formulas (table on the right, yellow).

	size (mm)																				
Samples	W1_w	W1_l	W1_h	W2_w	W2_l	W2_h	W3_w	W3_l	W3_h	W4_w	W4_l	W4_h	W5_w	W5_l	W5_h	W6_w	W6_l	W6_h	W7_w	W7_l	W7_h
Parental_1	4.90	3.50	4.90	5.40	4.60	6.70	8.40	4.20	6.70	4.50	7.40	7.70	6.70	7.70	7.80	7.70	7.80	7.40	8.60	6.70	6.50
Parental_2	2.70	6.90	4.00	6.10	4.10	7.70	10.20	4.60	4.00	6.50	11.20	7.60	12.30	7.80	9.20	10.40	9.60	6.00	13.60	13.30	12.50
Parental_3	6.80	6.40	6.00	5.40	4.30	5.50	4.60	4.60	6.40	6.80	6.80	7.80	7.40	7.80	7.30	9.90	7.50	8.80	11.90	10.30	10.60
Parental_8	7.00	6.40	6.30	5.60	5.40	5.80	5.60	3.70	4.30	6.20	7.80	4.00	5.90	7.80	5.40	6.40	10.50	5.70	8.70	12.00	7.70
ParentalAMX_1	6.30	6.00	5.70	3.60	4.30	4.60	5.70	6.10	6.80	7.50	5.80	4.90	6.30	6.80	6.30	5.30	6.80	5.00	7.80	6.70	6.70
ParentalAMX_4	6.80	4.60	5.80	4.30	5.60	5.10	4.80	4.50	4.30	5.50	5.30	5.60	4.10	4.70	4.70	4.40	5.00	3.80	6.90	5.90	5.70
ParentalAMX_5	6.90	4.80	5.40	7.10	4.00	4.70	6.10	6.80	4.20	9.70	6.70	5.70	10.30	8.10	6.50	11.30	9.30	6.90	12.10	13.30	11.80
CSC_1	3.90	7.90	7.60	6.60	4.90	6.60	5.00	7.40	5.80	7.70	4.90	4.50	4.90	7.80	5.50	3.90	7.80	4.20	4.70	6.90	6.10
CSC_3	6.80	4.90	6.00	5.60	8.90	5.00	5.00	8.10	5.40	6.20	10.30	5.10	10.00	6.20	6.00	6.50	9.40	5.40	7.10	11.10	6.10
CSC_5	7.70	5.00	7.90	5.60	6.80	6.80	8.60	5.30	6.00	10.80	5.10	6.20	7.40	9.40	7.60	7.30	11.30	7.90	13.60	8.80	8.10
CSC_7	6.90	6.60	6.60	6.10	7.20	5.30	6.30	6.80	6.50	7.90	6.80	7.50	6.70	7.70	7.10	7.20	7.80	7.20	8.70	7.80	8.90
CSC-AMX_1	5.70	6.40	5.60	5.60	4.70	6.20	6.40	5.40	6.70	6.40	6.90	7.70	8.50	7.60	7.90	8.40	8.40	8.00	9.80	7.80	7.40
CSC-AMX_3	9.40	4.10	3.90	6.90	4.10	4.40	5.20	4.90	5.80	4.60	5.60	5.10	4.80	6.10	5.00	5.80	5.10	4.80	6.00	5.60	5.60
CSC-AMX_4	5.70	8.00	6.10	6.80	6.00	6.20	4.90	4.90	7.90	7.80	4.70	4.30	7.60	4.80	5.00	5.70	8.00	5.60	6.80	5.50	4.70
CSC-AMX_5	7.70	6.30	6.50	6.80	6.00	6.20	5.70	6.70	5.60	6.10	7.60	6.30	7.70	10.00	8.40	11.80	7.20	6.10	12.40	7.80	5.90
CSC-AMX_6	6.20	6.20	6.00	6.00	4.40	4.10	4.40	4.00	3.90	4.00	4.70	3.10	4.40	3.90	4.80	4.60	4.00	3.40	5.50	3.90	3.50
CSC-AMX_7	5.60	8.10	5.20	7.70	5.60	4.90	6.20	9.10	5.30	7.90	8.70	7.30	9.60	8.60	8.00	10.60	8.20	8.00	11.00	9.00	9.90

	Volume = w*l*h / 2 (mm^3)						
Samples	W1	W2	W3	W4	W5	W6	W7
Parental_1	42.0	83.2	118.2	128.2	201.2	222.2	187.3
Parental_2	37.3	96.3	93.8	276.6	441.3	299.5	1130.5
Parental_3	130.6	63.9	67.7	180.3	210.7	326.7	649.6
Parental_8	141.1	87.7	44.5	96.7	124.3	191.5	401.9
ParentalAMX_1	107.7	35.6	118.2	106.6	134.9	90.1	175.1
ParentalAMX_4	90.7	61.4	46.4	81.6	45.3	41.8	116.0
ParentalAMX_5	89.4	66.7	87.1	185.2	271.1	362.6	949.5
CSC_1	117.1	106.7	107.3	84.9	105.1	63.9	98.9
CSC_3	100.0	124.6	109.4	162.8	186.0	165.0	240.4
CSC_5	152.1	129.5	136.7	170.7	264.3	325.8	484.7
CSC_7	150.3	116.4	139.2	201.5	183.1	202.2	302.0
CSC-AMX_1	102.1	81.6	115.8	170.0	255.2	282.2	282.8
CSC-AMX_3	75.2	62.2	73.9	65.7	73.2	71.0	94.1
CSC-AMX_4	139.1	126.5	94.8	78.8	91.2	127.7	87.9
CSC-AMX_5	157.7	126.5	106.9	146.0	323.4	259.1	285.3
CSC-AMX_6	115.3	54.1	34.3	29.1	41.2	31.3	37.5
CSC-AMX_7	117.9	105.6	149.5	250.9	330.2	347.7	490.1

	Volume = min^2 * max / 2 (mm^3)						
Samples	W1	W2	W3	W4	W5	W6	W7
Parental_1	30.0	70.9	74.1	78.0	175.1	213.6	181.7
Parental_2	25.2	64.7	81.6	236.6	374.2	187.2	1062.5
Parental_3	122.4	50.8	67.7	180.3	207.8	278.4	631.2
Parental_8	138.9	84.6	38.3	62.4	113.7	170.6	355.7
ParentalAMX_1	102.3	29.8	110.5	90.0	134.9	85.0	175.1
ParentalAMX_4	71.9	51.8	44.4	78.7	39.5	36.1	112.1
ParentalAMX_5	79.5	56.8	60.0	157.6	217.6	269.0	925.9
CSC_1	60.1	79.2	92.5	78.0	93.6	59.3	76.2
CSC_3	81.6	111.3	101.3	134.0	180.0	137.1	206.5
CSC_5	98.8	106.6	120.8	140.5	257.4	301.1	446.1
CSC_7	150.3	101.1	134.9	182.6	172.8	202.2	270.7
CSC-AMX_1	100.4	68.5	97.7	157.7	245.5	268.8	268.3
CSC-AMX_3	71.5	58.0	69.6	59.2	70.3	66.8	94.1
CSC-AMX_4	130.0	122.4	94.8	72.1	87.6	125.4	75.1
CSC-AMX_5	152.8	122.4	105.1	141.4	296.5	219.5	215.8
CSC-AMX_6	111.6	50.4	33.5	22.6	36.5	26.6	33.7
CSC-AMX_7	109.5	92.4	127.8	231.8	307.2	339.2	445.5

Figure S12C. Raw data on chemoprevention experiment (independent experiment Fig. S7, S10). Balb/c mice were given 100mg/kg AMX or PBS twice a week for 14 days followed by injection with MDA-MB-231 (P)arental cells or CSC-like cells (mammospheres). Tumor sizes were measured weekly (left). Tumor volumes were calculated by 2 different formulas (table on the right, yellow).